9926 Stock Overview
A biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of antibody drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Akeso, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$80.90 |
| 52 Week High | HK$105.50 |
| 52 Week Low | HK$26.45 |
| Beta | 0.60 |
| 1 Month Change | -1.58% |
| 3 Month Change | 38.29% |
| 1 Year Change | 64.43% |
| 3 Year Change | 512.88% |
| 5 Year Change | 184.36% |
| Change since IPO | 232.92% |
Recent News & Updates
Akeso, Inc.'s (HKG:9926) Shares Climb 29% But Its Business Is Yet to Catch Up
May 07
Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$104
May 03Recent updates
Akeso, Inc.'s (HKG:9926) Shares Climb 29% But Its Business Is Yet to Catch Up
May 07Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$104
May 03
Cadonilimab And Ivonescimab Trials Will Broaden Market Access
Apr 06 Akeso's strategic focus on bispecific antibodies and NRDL inclusion could drive significant revenue growth and expand market access.Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$82.91
Apr 01Akeso, Inc.'s (HKG:9926) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 16Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking
Sep 09Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Aug 30Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment
Jun 24Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding
Jun 19Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?
May 31Shareholder Returns
| 9926 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -6.7% | -6.4% | 2.1% |
| 1Y | 64.4% | 38.8% | 12.6% |
Return vs Industry: 9926 exceeded the Hong Kong Biotechs industry which returned 36.6% over the past year.
Return vs Market: 9926 exceeded the Hong Kong Market which returned 13% over the past year.
Price Volatility
| 9926 volatility | |
|---|---|
| 9926 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 9926's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9926's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 3,035 | Michelle Xia | www.akesobio.com |
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, PD-1, for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, PD-L1 for the treatment of recurrent or metastatic NPC.
Akeso, Inc. Fundamentals Summary
| 9926 fundamental statistics | |
|---|---|
| Market cap | HK$72.61b |
| Earnings (TTM) | -HK$556.92m |
| Revenue (TTM) | HK$2.30b |
31.6x
P/S Ratio-130.4x
P/E RatioIs 9926 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9926 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.12b |
| Cost of Revenue | CN¥301.24m |
| Gross Profit | CN¥1.82b |
| Other Expenses | CN¥2.34b |
| Earnings | -CN¥514.51m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 85.82% |
| Net Profit Margin | -24.22% |
| Debt/Equity Ratio | 58.4% |
How did 9926 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 01:28 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akeso, Inc. is covered by 40 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sharon Shi | BOCI Research Ltd. |
| Jiangqiao Tong | BOCI Research Ltd. |
| Yonglin Yan | BOCI Research Ltd. |